Vimarsana
Biggest News Aggregation in the World

Page 4 - B Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from B Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In B Cell Today - Breaking & Trending Today

Research redefines rheumatoid arthritis: Over 314,000 cells analyzed for precise treatment strategies - Vimarsana News

Research redefines rheumatoid arthritis: Over 314,000 cells analyzed for precise treatment strategies

A new paper recently published in Nature, reported the examination of synovial tissue from the joints of nearly 80 people with RA, in combination with RNA sequencing and surface protein analyses.

Researchers discover new mechanism of cancer treatment resistance - Vimarsana News

Researchers discover new mechanism of cancer treatment resistance

A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators.

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer - Vimarsana News

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

Intranasal vaccination: A potent one-time solution for comprehensive COVID-19 immunity - Vimarsana News

Intranasal vaccination: A potent one-time solution for comprehensive COVID-19 immunity

A single-dose intranasal vaccine effectively induces robust immune responses.

The Pathophysiology of IgAN and Use of Immunomodulating Therapies - Vimarsana News

The Pathophysiology of IgAN and Use of Immunomodulating Therapies

An expert nephrologist provides an overview of the pathophysiology of IgAN before discussing new immunomodulating therapies in clinical trials.